Specificity of Anti-DENV IgG ELISAs: Diagnostic Accuracy Study

Four Euroimmun ELISAs for dengue virus (DENV) were evaluated for sensitivity and specificity using sera from 22 Vietnamese patients and 580 control samples. The study, authored by Sandra Saschenbrecker and last updated in April 2026, found the novel dual-cut-off IgG ELISA 2.0 achieved 99.5% specificity with an alternative cut-off, minimizing cross-reactivity with West Nile and Zika viruses.

Use Cases

• Benchmarking ELISA test performance based on sensitivity and specificity metrics reported in the study
• Designing diagnostic strategies for acute and convalescent-phase dengue testing based on the described NS1, IgM, and IgG combination results
• Evaluating cross-reactivity in flavivirus-endemic regions based on the specificity data against West Nile and Zika virus samples
• Supporting pre-vaccination screening and epidemiological surveillance based on the convalescent-phase IgG dynamics described

Strengths

• Includes specificity assessments against 500 healthy donors and 40 patients each with West Nile and Zika virus infections
• Reports sensitivity for four distinct ELISA tests across three time points (acute, early convalescent, late convalescent)
• Data is shared under a permissive CC-BY-4.0 license

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is very small at 5.5 KB, indicating limited scope

Provenance

Source

figshare

Collection Method

Serological analysis of patient and control serum samples using ELISA tests.

Time Range

Sample collection phases described as acute (1–6 dpo), early convalescent (4–9 dpo), and late convalescent (13–19 dpo).

Freshness

Last updated 2026-04 27 17:43:19; freshness should be verified

Geography

Patient samples from Vietnam; control samples include healthy German blood donors.